Drugs / Pfizer-BioNTech COVID-19 Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04761822 | Apr 2021 → Apr 2022 | COVID-19, hypersensitivity reaction disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05175742 Comparator | Aug 2021 → Mar 2023 | — | Providence Therapeutics Holdings Inc. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pfizer-BioNTech COVID-19 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05175742 ↗ |
| Modality | Vaccine | “The Pfizer-BioNTech COVID-19 Vaccine (0.3 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.3 mL each) administered 3 weeks (21 days) apart.” NCT04761822 ↗ |
| Route | Intramuscular | “The Pfizer-BioNTech COVID-19 Vaccine (0.3 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.3 mL each) administered 3 weeks (21 days) apart.” NCT04761822 ↗ |